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Abstract (max 250 words; current 250 words) 40 
Tedizolid phosphate is approved for the treatment of acute bacterial skin and 41 
skin structure infection (ABSSSI) caused by Gram-positive bacteria in the USA, 42 
Europe, and other countries.  43 
In this multicenter, double-blind, Phase 3 study, 598 adult ABSSSI patients in 44 
China, Taiwan, the Philippines, and the USA were randomized to receive tedizolid 45 
200 mg, intravenous (IV)/ oral (PO), once daily for 6 days or linezolid 600 mg, IV/PO 46 
twice daily for 10 days. The primary endpoint was early clinical response rate at 48–47 
72 hours. Secondary endpoints included programmatic and investigator-assessed 48 
outcomes at end-of-therapy (EOT) and post-therapy evaluation (PTE) visits. Safety 49 
was also evaluated. 50 
In the intent-to-treat (ITT) population, 75.3% of tedizolid-treated patients and 51 
79.9% of linezolid-treated patients were early responders (treatment difference: –52 
4.6%; 95% confidence interval (CI): –11.2; 2.2). After exclusion of patients who 53 
never received study drug (tedizolid: n=8; linezolid: n=1; modified ITT), comparable 54 
early response rates were observed (tedizolid: 77.4%; linezolid: 80.1%; treatment 55 
difference: –2.7%; 95% CI: –9.4; 3.9). Secondary endpoints showed high and similar 56 
clinical success rates in the ITT and clinically evaluable (CE) populations at EOT and 57 
PTE visits (e.g. CE-PTE: tedizolid: 90.4%; linezolid: 93.5%). Both drugs were well 58 
tolerated and no death occurred. Eight patients experienced phlebitis with tedizolid 59 
versus none with linezolid, hence, drug-related treatment-emergent adverse events 60 
were reported in a slightly higher proportion in the tedizolid (20.9%) arm than 61 
linezolid arm (15.8%), respectively. 62 
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The study demonstrated that tedizolid in a primarily Asian population was an 63 
efficacious and well-tolerated treatment option for ABSSSI patients. 64 
 65 
Keywords: acute bacterial skin and skin structure infection; Asian patients; Chinese 66 
patients; linezolid; methicillin-resistant Staphylococcus aureus; oxazolidinone; 67 
randomized controlled Phase 3 trial; tedizolid phosphate  68 
Clinical trial registration number: NCT02066402 69 
70 
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Introduction 71 
Methicillin-resistant Staphylococcus aureus (MRSA) remains a challenging 72 
pathogen globally, with attributable increased risk of morbidity and/or mortality 73 
among patients with severe infections such as nosocomial pneumonia, surgical site 74 
infections, bacteremia, or endocarditis [1–6]. MRSA is also a concern in skin and soft 75 
tissue infections and in acute bacterial skin and skin structure infections (ABSSSIs) 76 
in the USA, Europe, and in Asian countries [7–11]. The prevalence of MRSA in some 77 
areas is considerable (e.g. ≥50%), such as in the USA, Russia, Latin American and 78 
Asian countries or region (e.g. Japan, Singapore, Taiwan) [12–14]. In China, the 79 
reported prevalence of MRSA has shown a declining trend over a 10-year period; 80 
however, it remains significant at >40% [15]. 81 
Owing to the diverse clinical presentation and varying level of severity of acute 82 
bacterial skin infections, the US Food and Drug Administration (FDA) recently 83 
specified the definition of ABSSSI, in order to strengthen the clinical development of 84 
antibiotics [8, 16]. ABSSSIs include cellulitis, erysipelas, wound infection and major 85 
cutaneous abscess with a lesion size of at least 75 cm2 [16] and are among the most 86 
frequent skin infections requiring hospitalization globally [8–10, 17–19]. These 87 
infections are predominantly caused by Gram-positive bacteria, including 88 
streptococci, staphylococci (including MRSA), and occasionally by enterococci or 89 
Gram-negative species [7, 8, 10, 11, 20]. Considering the risk of MRSA is a key step 90 
in the management of ABSSSI patients when selecting the most appropriate 91 
antibiotic [20–22], particularly in areas where prevalence is significantly high or 92 
relevant risk factors are present (e.g. previous MRSA infection or colonization, 93 
previous hospitalization, previous antibiotic use, invasive procedures, or chronic 94 
open wounds [20]).  95 
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New antibiotics with favorable safety profiles and oral formulations to maximize 96 
their benefit for outpatient management [23] are still needed in China for the 97 
treatment of ABSSSI and other Gram-positive infections. Tedizolid phosphate 98 
(hereafter referred to as tedizolid) 200 mg, intravenous (IV) and/or oral (PO), once 99 
daily for 6 days, was approved by the FDA and European Medicines Agency (EMA) 100 
for the treatment of ABSSSI based on the results of two randomized, double-blind, 101 
active-controlled, multicenter, international Phase 3 clinical studies [24, 25]. These 102 
studies demonstrated the non-inferiority of tedizolid to linezolid in the early clinical 103 
response rate and in all secondary endpoints. In addition, a favorable safety profile in 104 
terms of gastrointestinal and hematological side-effects was observed [24–28]. 105 
The objective of the current study (NCT02066402) was to compare the efficacy 106 
and safety of tedizolid 200 mg, IV/PO, once daily, for 6 days to linezolid 600 mg, 107 
IV/PO, twice daily for 10 days in patients with ABSSSI who were enrolled primarily in 108 
Asian countries (China, Taiwan, the Philippines) and the USA. 109 
 110 
Results 111 
Patient disposition 112 
Patient flow through the study is shown in Figure 1. A total of 598 patients with 113 
ABSSSI were randomized to receive either tedizolid (N=300) or linezolid (N=298) 114 
(intent-to-treat [ITT] population), after excluding 57 patients who failed screening (not 115 
meeting all inclusion criteria: 24; at least one exclusion criteria: 24; withdrawal: 7; 116 
technical problems: 2; Table S1).  117 
 118 
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Baseline demographics and disease characteristics 119 
Baseline demographic and infection characteristics were similar between 120 
treatment arms (Table 1). The majority of patients (tedizolid: 63.7%; linezolid: 121 
64.8%) were Asian/Chinese, and approximately one third of patients were Caucasian. 122 
In the ITT population, the majority of patients had cellulitis/erysipelas (Table 1), and 123 
most wound infections were post-traumatic wounds (tedizolid: n=67, linezolid: n=68). 124 
The percentage of patients with a confirmed pathogen at baseline 125 
(microbiological ITT [MITT] population) was similar between treatment arms 126 
(tedizolid: 37.7%; linezolid: 42.3%), and of those, 25.7% in the tedizolid arm and 127 
25.4% in the linezolid arm had MRSA at baseline (Table 1). The rate of isolation of 128 
Gram-positive pathogens was the lowest among patients with cellulitis (tedizolid: 129 
16.7%, linezolid: 18.3%) and much higher among patients with major cutaneous 130 
abscess (tedizolid: 62.5%, linezolid: 79.5%) or with wound infections (tedizolid: 131 
82.4%, linezolid: 88.2%), respectively. 132 
Although the median lesion size was similar between treatment arms, the mean 133 
and range of lesion sizes were greater in the tedizolid arm versus the linezolid arm 134 
(Table 1), however, the difference was not significant. The difference in mean value 135 
of lesion size at baseline was more prominent in patients with confirmed pathogens 136 
versus those with suspected pathogens (Table S2). A low proportion of patients 137 
received aztreonam (tedizolid: 3.3%, linezolid: 5.7%) or metronidazole (tedizolid: 138 
1.0%, linezolid: 1.0%), which were permitted concomitant antibiotics according to the 139 
protocol. 140 
 141 
Primary endpoint 142 
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In the ITT population, 226 patients out of 300 (75.3%) in the tedizolid arm and 143 
238 patients out of 298 (79.9%) in the linezolid arm achieved early clinical response 144 
(i.e. ≥20% reduction in lesion size, no concomitant antibiotic used and no death 145 
occurred) at 48–72 hours. The difference in early clinical response rates between 146 
treatment arms was –4.6%, with the lower boundary of the 95% confidence interval 147 
(CI) being below –10% (i.e. 95% CI: –11.2; 2.2), indicating that the non-inferiority 148 
criterion was not met (Table 2). Eight patients in the tedizolid arm due to consent 149 
withdrawal (n=7), non-compliance with study drug (n=1), and one patient in the 150 
linezolid arm due to lost to follow-up did not receive the study drug after 151 
randomization and were therefore considered as having indeterminate response (ITT 152 
population).  153 
In the post-hoc analysis of the modified ITT population (mITT; after exclusion of 154 
eight randomized patients in the tedizolid arm and one randomized patient in the 155 
linezolid arm without receiving any study drug), comparable early clinical response 156 
rates were demonstrated between treatment arms at 48–72 hours (tedizolid: 77.4%, 157 
linezolid: 80.1%; treatment difference: –2.7%; 95% CI: –9.4; 3.9) (Table 2). 158 
 159 
Secondary endpoints 160 
Analyses of the programmatic and investigator assessment of clinical success 161 
rates demonstrated that all pre-specified secondary endpoints were met (Table 2). 162 
Comparable efficacy between tedizolid and linezolid was demonstrated at end-of-163 
therapy (EOT) in the ITT population (tedizolid: 82.0%, linezolid: 84.2%; treatment 164 
difference: –2.2%; 95% CI: –8.3; 3.8) and in clinically evaluable (CE)-EOT population 165 
(tedizolid: 89.7%, linezolid: 91.8%; treatment difference: –2.1%; 95% CI: –7.4; 3.2) 166 
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for the programmatic clinical outcome. Furthermore, rates of investigator assessment 167 
of clinical success were comparable at the post-therapy evaluation (PTE) visit in the 168 
ITT (tedizolid: 79.7%, linezolid: 81.9%; treatment difference: –2.2%; 95% CI: –8.6; 169 
4.1) and CE-PTE populations (tedizolid: 90.4%, linezolid: 93.5%; treatment 170 
difference: –3.1%; 95% CI: –8.4; 2.0), respectively. 171 
In both treatment arms, improvement in the overall clinical status that was 172 
compatible with continuation of therapy was seen in a similar proportion of patients 173 
at 48–72 hours (tedizolid: 89.0%, linezolid: 90.6%) and at Day 7 (tedizolid: 90.8%, 174 
linezolid: 87.9%) based on investigator assessment in the modified ITT population 175 
(Table S3) and also in the ITT population (data not shown).  176 
 177 
Investigator assessment of clinical signs and symptoms 178 
Investigator assessment of systemic, regional and local signs and symptoms of 179 
ABSSSI were evaluated in post-hoc analyses in the mITT population. The numbers 180 
of patients with a valid assessment at baseline for all investigated parameters were 181 
comparable between treatment arms. The results demonstrated that over the course 182 
of the study period, the degree of improvements in all signs and symptoms (i.e. 183 
severity of lymph node tenderness, lymphadenopathy, erythema, edema, and 184 
induration) was similar between tedizolid and linezolid arms (Table S4). Both 185 
tedizolid and linezolid treatments resulted in a similar absolute reduction in the mean 186 
lesion size at sequential time points (Day 2, 48–72 hours, Day 7, EOT and PTE 187 
visits), although slightly greater reductions were observed in tedizolid-treated 188 
patients versus linezolid-treated patients with confirmed pathogen at baseline in 189 
post-hoc analyses (Table S5).  190 
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At baseline, a small proportion of patients in both treatment arms (tedizolid: 191 
22.9% vs linezolid: 28.4%) had fever. The median time to resolution of fever was 192 
41.2 hours in the tedizolid arm and 40.9 hours in the linezolid arm. Changes in 193 
patient-reported pain scores from baseline were similar between the two arms, as 194 
measured by either visual analogue scale (VAS) or faces rating scale (FRS) scoring 195 
(Table S6). 196 
 197 
Efficacy results by infection type 198 
In the ITT population at 48–72 hours, the early clinical response rate was 199 
numerically higher in the tedizolid arm than in the linezolid arm (tedizolid: 95.0% vs 200 
linezolid: 84.6%, respectively) among patients with major abscess. The early clinical 201 
response rate was numerically lower in the tedizolid arm than in the linezolid arm 202 
among patients with cellulitis/erysipelas (tedizolid: 70.3% vs linezolid: 78.0%) and 203 
wound infection (tedizolid: 77.9% vs linezolid: 82.4%). In the CE-PTE population at 204 
the PTE visit, investigator assessment of clinical success was demonstrated with 6-205 
day tedizolid and 10-day linezolid treatments, respectively, in 97.0% and 96.4% of 206 
patients with major abscess, in 86.9% and 92.1% of patients with cellulitis/erysipelas, 207 
and in 95.9% and 96.1% of patients with wound infection. 208 
 209 
Microbiological results 210 
All S. aureus, methicillin-susceptible S. aureus (MSSA), MRSA and other 211 
Gram-positive pathogens had a tedizolid minimum inhibitory concentration (MIC) of 212 
≤0.5 µg/mL and linezolid MIC of ≤4 µg/mL. For both MRSA and MSSA, tedizolid MIC 213 
ranged between 0.25 and 0.5 µg/mL in the tedizolid arm and linezolid MIC ranged 214 
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between 1.0 and 4.0 µg/mL in the linezolid arm. Overall, the rates of favorable 215 
microbiological response were similar in both treatment arms in the MITT (tedizolid: 216 
77.0% vs linezolid: 75.4%; treatment difference: 1.6%; 95% CI: –9.4; 12.4) and 217 
microbiologically evaluable (tedizolid: 94.0% vs linezolid: 90.5%; treatment 218 
difference: 3.5%; 95% CI: –4.9; 12.0) populations for patients with a confirmed 219 
Gram-positive pathogen at baseline (Figure 2). At the PTE visit, the rates of 220 
investigator assessment of clinical success by pathogen were high, although some 221 
numerical differences between treatment arms were seen due to low patient 222 
numbers (Table 3). In an exploratory post-hoc analysis, evaluation of early clinical 223 
response for patients with confirmed pathogen at baseline in the MITT and modified 224 
MITT population showed similar rates between tedizolid and linezolid treatment arms 225 
(MITT: tedizolid [N=113]: 78.8% vs linezolid [N=126]: 81.0%; modified MITT: 226 
tedizolid [N=110]: 80.9% vs linezolid [N=125]: 81.6%). These post-hoc analyses data 227 
should be interpreted with caution. 228 
 229 
Safety findings 230 
Both tedizolid and linezolid treatments were well tolerated. The incidence of 231 
treatment-emergent adverse events (TEAEs) was comparable between tedizolid 232 
(49.7%) and linezolid (45.8%) arms, and most TEAEs were mild or moderate in 233 
intensity (Table 4). Numerically a higher proportion of tedizolid-treated patients had 234 
drug-related TEAEs compared with linezolid-treated patients (20.9% vs 15.8%) 235 
(Table 4). The proportions of patients experiencing serious TEAEs and treatment 236 
discontinuation were low and similar between treatment arms. No drug-related 237 
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serious TEAE or death occurred in either treatment arm. Discontinuation due to 238 
serious TEAEs occurred only in the linezolid arm (n=3) (Table 4). 239 
The summary of drug-related adverse events occurring in ≥1% of patients in 240 
either treatment arm is shown in Table 5. Of note, in the tedizolid arm, eight patients 241 
(2.7%) experienced phlebitis that was related to study drug compared with none in 242 
the linezolid arm. Other drug-related TEAEs occurred at similar rates between 243 
tedizolid and linezolid arms (Table 5). The rates of overall gastrointestinal (GI) 244 
TEAEs were low and comparable between the two treatment arms (tedizolid: 8.9%; 245 
linezolid: 10.4%). 246 
Rates of substantially abnormal findings in laboratory investigations are shown 247 
in Table S7. Levels of the hepatic enzymes alanine aminotransferase (ALT) and 248 
aspartate aminotransferase (AST) were elevated in a numerically higher proportion 249 
of patients treated with linezolid (ALT: 7.2%; AST: 4.6%) than tedizolid (ALT: 5.1%; 250 
AST: 2.2%) (Table S7). Hematological findings in the safety population showed that 251 
a very low number of patients in both treatment arms experienced substantially 252 
abnormal values of hemoglobin (tedizolid: 0 vs linezolid: 2), absolute neutrophil 253 
count (tedizolid: 0 vs linezolid: 3) or platelet count (tedizolid: 2 vs linezolid: 1) (Table 254 
S7). The proportion of patients with abnormal platelet values (including those with 255 
normal or abnormal baseline values and non-missing data at the subsequent visits) 256 
was also low and comparable between treatment arms: Day 7–9 (tedizolid: 2.1% 257 
[5/234] vs linezolid: 0% [0/218]), Day 11–13 (tedizolid: 4.4% [11/250] vs linezolid: 258 
3.4% [8/236]), last dose of active drug (tedizolid: 2.1% [5/234] vs linezolid: 3.4% 259 
[8/236]) and at any post-baseline visit through to last dose of active drug (tedizolid: 260 
3.4% [8/234] vs linezolid: 4.5% [10/224]). 261 
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There were no remarkable findings for vital signs, electrocardiogram findings, 262 
Clostridium difficile-associated diarrhea, lactic acidosis and neurological 263 
assessments. 264 
 265 
Discussion  266 
This was the third international, multicenter, randomized, double-blind, double-267 
dummy Phase 3 controlled study comparing the efficacy and safety of tedizolid 200 268 
mg once daily for 6 days and linezolid 600 mg twice daily for 10 days in patients with 269 
ABSSSI, who were primarily enrolled in Asian countries. The ESTABLISH-1 (PO 270 
only) and -2 (IV/PO, switching from IV to PO when meeting criteria) studies 271 
previously demonstrated the non-inferiority of tedizolid to linezolid in terms of early 272 
clinical response rate at 48–72 hours and in clinical success rates at later time points 273 
[24–26].  274 
The findings of the current study demonstrated that the non-inferiority of 275 
tedizolid to linezolid in the early clinical response rate (i.e. ≥20% reduction in lesion 276 
size from baseline within 72 hours after first infusion of study drug was required in 277 
the ITT population) was inconclusive. The lower limit of the 95% CI was below the –278 
10% in the ITT population (including all randomized patients) indicating that non-279 
inferiority was not met. However, an imbalance in the number of randomized but 280 
untreated patients was observed (tedizolid: 8 vs linezolid: 1) in this study. After 281 
excluding these patients who never received study drug in a post-hoc analysis, 282 
comparable early clinical response rates at 48–72 hours were demonstrated 283 
between tedizolid and linezolid treatment arms in the modified ITT population. At 284 
later protocol-specified time points, the rates of sustained programmatic clinical 285 
response at EOT and investigator assessment of clinical success at the PTE visit 286 
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(which is the primary endpoint defined by EMA) were comparable between the two 287 
treatment arms. Both treatments were well tolerated, and the study did not reveal 288 
any new safety signals with tedizolid treatment in this primarily Asian population, with 289 
the exception of a higher reported rate of drug-related phlebitis in the tedizolid arm. 290 
The design of the current study, closely resembling that of ESTABLISH-2 [25], 291 
allowed the switch from IV to PO therapy at the discretion of the treating physician. A 292 
Phase 1 study conducted in healthy Chinese individuals demonstrated a high oral 293 
bioavailability of tedizolid (i.e. 85.5%) suggesting that no dose adjustment is needed 294 
when switching from IV to PO therapy in Chinese patients [29]. The mean duration of 295 
IV treatment was approximately 4.2 days and compliance to study drug was high in 296 
both treatment arms.  297 
The patient population enrolled in the current study had some numerical 298 
differences in baseline demographic parameters and disease characteristics 299 
compared with those enrolled in the ESTABLISH studies. Thus, the proportion of 300 
patients with cellulitis/erysipelas was 64% in the current study compared with 45% in 301 
ESTABLISH-1 and -2 [24–26].  302 
Additionally, there was a non-significant difference between the two treatment 303 
arms in the range of lesion sizes at baseline (tedizolid: 75–6272 cm2; linezolid: 77–304 
2664 cm2). There is no defined maximum lesion size for enrolment into ABSSSI 305 
studies [16]. Furthermore, this was the first study in China using ≥20 % reduction in 306 
lesion size, measured by the ruler method, at 48–72 hours as the primary endpoint, 307 
which may limit comparison with other trials. Despite the imbalance in the mean and 308 
maximum lesion sizes, the investigators demonstrated in the mITT population a 309 
similar trend between the two treatment arms in the absolute reduction of lesion size 310 
from Day 2 up to the PTE visit, which may indicate continuing improvements in local 311 
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signs and symptoms even in patients with very large lesions (e.g. cellulitis/erysipelas 312 
with an area of 6272 cm2). The lesion size reductions were complemented by similar 313 
trends in improvements of lymphadenopathy, time to resolution of fever, changes in 314 
pain scores, and declining severity of erythema, edema and induration among 315 
randomized and treated patients, suggesting that patients responded to both 316 
treatments from an early time point.  317 
In real-life clinical practice, a change in antibiotic treatment is recommended if 318 
signs and symptoms of skin infections do not improve or if the patient deteriorates at 319 
an early stage of management, and/or when microbiological information becomes 320 
available and escalation or de-escalation of antibiotic treatment is required [30]. In 321 
the current study, the blinded investigators continued the study drug therapy based 322 
on the overall assessment of clinical status in approximately 90% of patients in both 323 
treatment arms at 48–72 hours and at Day 7. Furthermore, the number of patients 324 
who discontinued therapy due to TEAEs was low in both treatment arms. These 325 
findings may reflect current clinical practice [31]. 326 
The mismatch between the proportion of patients who were early responders 327 
according to the protocol and achieved ≥20% reduction in lesion size and those 328 
patients with gradual improvements in overall clinical status of ABSSSI from Day 2 329 
up to the PTE visit might correspond with the findings by Nathwani et al. [32]. 330 
Integrated analyses of the ESTABLISH studies suggested that early clinical 331 
response was highly predictive of late clinical success at the PTE visit; however, the 332 
lack of early clinical response correlated poorly with clinical failure at later time points 333 
[31, 32]. Thus, the clinical decision to continue therapy when patients improve in 334 
their clinical status may supersede the evaluation of a single parameter (i.e. lesion 335 
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size measurement only). Similar findings were observed in the ESTABLISH-2 study 336 
in terms of continuation of therapy by blinded investigators [25].  337 
The high clinical success rates seen in the current study with 6-day tedizolid 338 
treatment in the clinically evaluable population at EOT (89.7%) and PTE (90.4%) 339 
visits were in agreement with those in the ESTABLISH-1 and -2 studies 340 
(ESTABLISH-1: EOT: 80.2%, PTE: 94.6%; ESTABLISH-2: EOT: 90.0%, PTE: 92.0%, 341 
respectively) [24, 25]. Analysis of the integrated ESTABLISH studies by Sandison et 342 
al. demonstrated that regardless of the severity of the baseline disease 343 
characteristics (e.g. presence or absence of fever, lymphadenopathy, elevated white 344 
blood cell count), tedizolid and linezolid both achieved high clinical success rates at 345 
the PTE visit [33]. Furthermore, at the PTE visit, high clinical success rates (current 346 
study: 86.9%–97.0%; ESTABLISH-1: 93.2%–97.4%; ESTABLISH-2: 91.0%–95.0%) 347 
were seen in all three studies in all infection types (i.e. cellulitis/erysipelas, wound 348 
infection, or major abscess), suggesting consistent comparable clinical efficacy of 6-349 
day tedizolid in patient populations with high protocol and treatment compliance 350 
across geographical regions.  351 
The proportion of any confirmed baseline pathogen (~40.0%) or MRSA (~25%) 352 
was lower in this study than in the ESTABLISH studies (~62% and ~35%, 353 
respectively). The high proportion of cellulitis/erysipelas in this study limited the 354 
number of patients with a confirmed pathogen at baseline, as biospecimens taken 355 
from cellulitis patients rarely yield a pathogen [34]. Despite a lower yield of confirmed 356 
pathogens, rates of eradication and presumed eradication against most pathogens 357 
were comparable between tedizolid and linezolid treatments in both the MITT and 358 
ME populations. The high eradication rates were supported by the 100% 359 
susceptibility of baseline pathogens to tedizolid and translated into high rates of 360 
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clinical success assessed by the investigator; these results are similar to those 361 
observed in previous ABSSSI studies with tedizolid [24, 25]. Global ongoing 362 
surveillance studies report that susceptibility of S. aureus, MRSA, beta-hemolytic 363 
streptococci, viridans group streptococci, and enterococci, isolated from skin 364 
biospecimens or blood, to tedizolid is at least 4-times greater than to linezolid [35, 365 
36], suggesting that tedizolid could be an effective choice for the treatment of Gram-366 
positive infections. 367 
Both treatments were well tolerated and no new safety signal was reported in 368 
this primarily Asian population. A slightly higher incidence of drug-related TEAEs 369 
was observed with tedizolid than linezolid treatment, which was attributed to the 370 
higher number of patients (n=8) experiencing phlebitis at the infusion site (without 371 
discontinuation and considered not serious events) compared with none in the 372 
linezolid arm. This rate (20.9%) of drug-related TEAEs in the tedizolid arm of the 373 
current study was similar to that of the integrated ESTABLISH studies (22.4%) [27]. 374 
Furthermore, the overall rates of GI TEAEs (including those related to study drug) 375 
and abnormal hematological findings were lower in both treatment arms compared 376 
with integrated data from the ESTABLISH studies [26]. However, the lower limit of 377 
normal value of the platelet count was different to that used in the previous studies, 378 
and therefore, results of the incidence of thrombocytopenia must be viewed with 379 
caution when comparing ABSSSI studies. 380 
The favorable safety profile of IV/PO tedizolid 200 mg once daily treatment, for 381 
approximately 10 days, has recently been demonstrated in a Phase 3 clinical study 382 
in Japanese patients with complicated skin and soft tissue infections in terms of 383 
hematological and GI drug-related TEAEs versus linezolid [37]. Additionally, 384 
according to a case series publication, tedizolid treatment for an extended duration 385 
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of 7–14 days in four severe and complex ABSSSI patients was effective and well 386 
tolerated without any reported adverse event [38].  387 
 388 
Conclusion 389 
In conclusion, the study demonstrated that treatment with tedizolid 200 mg once 390 
daily for 6 days achieved a consistent level of clinical efficacy in a primarily 391 
Asian/Chinese ABSSSI patient population compared with linezolid. Tedizolid 392 
treatment was well tolerated without any previously unidentified adverse event and 393 
only a low risk of hematological or GI side-effects was observed. Tedizolid 200 mg 394 
once daily for 6 days, with a potential switch from IV to PO therapy, seems to be an 395 
appropriate choice for the treatment of Chinese or other Asian patients diagnosed 396 
with ABSSSI. 397 
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Patients and methods 398 
 399 
Study design 400 
This was a randomized (1:1), double-blind, double-dummy, multicenter, active-401 
controlled, non-inferiority Phase 3 clinical registration study enrolling patients with 402 
ABSSSI. The study was conducted between 4 March 2014 and 18 April 2016 in 39 403 
centers in China, 6 centers in Taiwan, 2 centers in the Philippines, and 5 centers in 404 
the USA. This study was registered with ClinicalTrials.gov (NCT02066402). 405 
 406 
Ethical regulations 407 
All patients or their legal representative provided written consent to participate 408 
in the study. The study was conducted according to the Declaration of Helsinki, and 409 
approval of the clinical study protocol from local ethical committees or institutional 410 
review board was obtained at all centers according to Good Clinical Practice 411 
guidelines, local ethical laws, regulations and/or organizations.  412 
 413 
Inclusion criteria 414 
Adult (age ≥18 years) male or female patients were eligible for enrollment if 415 
they were diagnosed with ABSSSI (i.e. cellulitis, erysipelas, major cutaneous 416 
abscess, or wound infection [superficial incision surgical site occurring within 30 days 417 
following only clean surgery or post-traumatic infection]), which was caused by 418 
suspected or confirmed Gram-positive bacteria, who required IV antibiotic therapy, 419 
had adequate access for at least two IV doses of study drug, and their local 420 
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symptoms started within 7 days prior to screening. The minimum lesion size for all 421 
three ABSSSI types was 75 cm2 (measured head to toe, length  width by flexible 422 
ruler method). 423 
All patients had at least one of the following regional or systemic signs of 424 
infection: 1) lymph node tenderness and increase in volume or palpable proximal to 425 
the primary ABSSSI [lymphadenopathy]; 2) fever; 3) white blood cell count ≥10,000 426 
cell/mm3 or <4000 cell/mm3 blood; or 4) >10% immature neutrophils. In patients with 427 
cellulitis/erysipelas, at least two of the local signs of infection was present (i.e. 428 
erythema, edema, induration, localized warmth, pain or tenderness on palpation). In 429 
patients with major cutaneous abscess, the presence of pus in the dermis or deeper 430 
was accompanied within 24 hours by erythema, edema, and/or induration extending 431 
≥5 cm in the shortest distance from the peripheral margin of the abscess and also by 432 
at least one of the following signs: 1) fluctuance; 2) incision and drainage required; 3) 433 
purulent or seropurulent drainage; 4) localized warmth; 5) pain or tenderness on 434 
palpation. In patients with wound infection, the presence of purulent drainage was 435 
accompanied by erythema, edema, and/or induration extending ≥5 cm in the shortest 436 
distance from the peripheral margin of the wound. A biospecimen taken by aspiration, 437 
biopsy, incision, or deep swab was required for patients with major abscess or 438 
wound infection. 439 
 440 
Key exclusion criteria 441 
Key exclusion criteria were uncomplicated skin and skin structure infection (e.g. 442 
minor abscess, minor wound infection, impetiginous lesion); infection associated with 443 
a prosthetic device or a vascular catheter or thrombophlebitis; systemic antibiotic 444 
 o
n
 M
ay 21, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Xiaoju Lv, et al. Tedizolid Phase 3 ms Revised  March 30, 2019 
21 
therapy with activity against Gram-positive bacteria within 24 hours prior to the first 445 
infusion of study drug; confirmed Gram-negative bacteria in association with the 446 
ABSSSI, except for patients with wound infection, who were allowed to be treated 447 
with concomitant systemic aztreonam and/or metronidazole to cover aerobic and/or 448 
anaerobic Gram-negative pathogens. Exclusion criteria are listed in full in the 449 
Supplementary material. 450 
 451 
Treatments 452 
Patients were randomized to receive IV/PO tedizolid phosphate 200 mg once 453 
daily for 6 days followed by placebo for 4 days or IV/PO linezolid 600 mg, twice daily 454 
for 10 days. A minimum of two doses of study drug was administered as IV infusion 455 
and, at the discretion of the treating investigator, the patient could be switched to PO 456 
treatment for the rest of the treatment duration. 457 
In order to maintain blinding, a double-dummy treatment design was used: 458 
patients in the tedizolid arm received one active dose of tedizolid plus two doses of 459 
placebo-linezolid; patients in the linezolid arm received two active doses of linezolid 460 
plus one dose of placebo-tedizolid. Doses were administered either as IV infusion or 461 
PO tablet. All patients, the investigators, hospital staff and nurses responsible for 462 
patient care and clinical evaluations, and the sponsor were blinded to treatments.  463 
 464 
Patient populations 465 
The efficacy of tedizolid and linezolid was compared in the intent-to-treat (ITT), 466 
clinically evaluable (CE), microbiological ITT (MITT) and microbiologically evaluable 467 
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(ME) populations. The ITT population comprised all randomized patients assigned to 468 
either treatment arm. The CE population included patients who received all study 469 
treatments without major protocol violation, did not receive any concomitant 470 
potentially effective antibiotic treatment, and completed the assessment at the end-471 
of-therapy visit (CE-EOT) and/or at the post-therapy evaluation visit (CE-PTE). The 472 
MITT population comprised all ITT randomized patients with a confirmed Gram-473 
positive pathogen at baseline. The ME population comprised all patients valid for the 474 
CE-PTE population who had a confirmed Gram-positive pathogen at baseline. The 475 
safety of tedizolid and linezolid was compared in the safety (SAF) population, which 476 
included all randomized patients who received at least one dose of study drug in 477 
either treatment arm.  478 
The efficacy of tedizolid and linezolid was also compared in a post-hoc analysis 479 
in the modified intent-to-treat population (mITT), which excluded patients who did not 480 
receive any study drug. 481 
 482 
Endpoints and definition of clinical outcomes 483 
The primary objective of the study was to demonstrate that IV/PO tedizolid 484 
200 mg once-daily treatment for 6 days was non-inferior to IV/PO linezolid 600 mg 485 
twice-daily treatment for 10 days in the early clinical response at 48–72 hours in the 486 
ITT population. 487 
Patients were evaluated as responders or non-responders to therapy. The early 488 
clinical response was defined as ≥20% reduction in lesion size (length  width of 489 
erythema, edema, and/or induration from head to toe, measured with a flexible ruler), 490 
in a patient who did not receive any prohibited concomitant systemic antibiotic and 491 
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did not die within 72 hours after the first infusion of study drug. Patients were 492 
evaluated as non-responder if any of the following criteria was met: 1) <20% 493 
reduction in lesion size compared with baseline; 2) any systemic concomitant 494 
antibiotic was administered with activity against the baseline pathogen within 495 
72 hours after the first infusion of study drug; 3) death occurred within 72 hours after 496 
the first infusion of study drug. Patients with missing data for the primary objective 497 
were considered as non-responders. Patients for whom clinical response could not 498 
be determined were considered as indeterminate and calculated as non-responder in 499 
the primary outcome analysis. 500 
The secondary planned objectives of the study included programmatic and/or 501 
investigator assessment of clinical outcomes (i.e. clinical success, clinical failure, or 502 
indeterminate) at the EOT and PTE visits. Full detailed definitions of clinical 503 
responses are described in the Supplementary material. The rates of sustained 504 
(programmatic) objective clinical response in both treatment arms were compared at 505 
the EOT visit in the ITT population and the CE-EOT population. The rates of 506 
investigator assessment of clinical success at the EOT and PTE visits in the ITT and 507 
CE-EOT or CE-PTE populations, respectively, were also compared. Patients in 508 
whom treatment outcome was considered by the investigator to be a clinical failure 509 
at the EOT visit were carried forward as clinical failures to the PTE visit in the ITT 510 
and the CE-PTE populations. 511 
Pre-specified other endpoints included investigator assessment of changes in 512 
systemic (i.e. fever, white blood cell count, immature neutrophils), regional (i.e. 513 
lymph node tenderness, lymphadenopathy), and local (i.e. lesion size, erythema, 514 
edema, fluctuance, induration, pain to palpation, drainage, localized warmth) signs 515 
and symptoms of infection over the course of the study (i.e. Day 1, Day 2, 48–516 
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72 hours, Day 7, EOT, PTE, late follow-up). Changes in pain score compared with 517 
baseline level over the course of the study were evaluated by the investigator using 518 
visual analogue scale (VAS) and the Wong–Baker Faces Rating Scale (FRS) 519 
methods. Time to resolution of fever was assessed by the investigator. 520 
Other pre-specified clinical efficacy endpoints included investigator assessment 521 
of clinical success rates overall and per pathogen in both treatment arms in the MITT 522 
and ME populations at the PTE visit. Rates of per-patient favorable response and 523 
per-pathogen microbiological response in the MITT and ME populations were also 524 
assessed at the PTE visit. Favorable microbiological response was defined as 525 
eradication and presumed eradication, whereas unfavorable microbiological 526 
response was defined as persistence, presumed persistence, and indeterminate 527 
responses. 528 
 529 
Microbiological evaluation 530 
Baseline pathogens and their antibiotic susceptibility pattern isolated from 531 
biospecimens, which were taken by needle aspiration, biopsy, deep swab, or incision 532 
from the primary lesion site and/or blood samples, were evaluated in three central 533 
laboratories (Covance Central Laboratory Services, Indianapolis, USA; Singapore; 534 
and Shanghai, China). Susceptibility of baseline pathogens to tedizolid and linezolid 535 
defined by the minimum inhibitory concentration (MIC) was determined according to 536 
Clinical and Laboratory Standards Institute guidelines [39, 40]. 537 
 538 
Safety investigations 539 
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Safety investigations included reporting of adverse events (MedDRA 16.0 or 540 
higher), laboratory evaluations (e.g. complete blood cell count, hepatic enzymes, 541 
renal function, and blood chemistry), vital signs, electrocardiogram parameters, 542 
physical examinations, emergence of Clostridium difficile-associated diarrhea, and 543 
neurotoxicity evaluations. 544 
 545 
Statistical analysis 546 
For the primary efficacy endpoint analysis, the number and percentage of 547 
patients in each response category (i.e. responder, non-responder, or indeterminate) 548 
for both treatment arms, and also an un-stratified 95% confidence interval (CI) by the 549 
Miettinen and Nurminen method [41] were calculated. If the lower limit of the 95% CI 550 
for the treatment difference between rates of responders was greater than –10%, 551 
non-inferiority of tedizolid to linezolid was concluded in the ITT population. 552 
For the secondary efficacy endpoints analyses, the number and percentage of 553 
patients with programmatic or investigator-assessed clinical outcomes (i.e. clinical 554 
success, clinical failure, and indeterminate) for both treatment arms at the EOT and 555 
PTE visits were determined in the ITT, CE-EOT and CE-PTE populations, 556 
respectively. Two-sided 95% CIs were computed for the observed treatment 557 
differences in the clinical success rates using the method of Miettinen and Nurminen 558 
[41], and non-inferiority was concluded or rejected. 559 
Post-hoc analyses were performed in the mITT population, after exclusion of 560 
patients who did not receive any study drug, for early clinical response rate and 561 
investigator assessment of changes in local, regional, and systemic signs and 562 
symptoms of the primary ABSSSI lesion. 563 
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The safety parameters were evaluated by descriptive statistical methods. 564 
All variables were analyzed by descriptive statistical methods. Missing data 565 
were not imputed for descriptive analyses. The number of data available, mean, 566 
standard deviation (SD), minimum, median, and maximum were calculated for 567 
continuous data. Frequency tables were generated for categorical data, and only 568 
patients with available data were included in the denominators. Statistical evaluation 569 
was performed using SAS release 9.2 or higher (SAS Institute Inc., Cary, NC, USA).  570 
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Table 1. Demographic and baseline characteristics of patients with acute bacterial 772 
skin and skin structure infections (intent-to-treat population) 773 
Parameter Tedizolid 
phosphate  
N=300 
Linezolid 
N=298 
Male patient, n (%)  209 (69.7) 192 (64.4) 
Age, years   
Mean (range) 45.7 (18–85) 47.5 (18–85) 
65–75 years, n (%) 33 (11.0) 35 (11.7) 
>75 years, n (%) 8 (2.7) 18 (6.0) 
Race, n (%)   
White 101 (33.7) 93 (31.2) 
Asian 191 (63.7) 193 (64.8) 
Not reported 2 (0.7) 1 (0.3) 
Other 6 (2.0) 11 (3.7) 
BMI, kg/m2    
Mean (range) 26.29a (16.3–63.4) 25.58 (15.2–50.0) 
Comorbidities, n (%)   
History of diabetes mellitus 26 (8.7) 35 (11.7) 
Renal impairment (mild/moderate) 71b (24.1) 87c (29.5) 
Hepatobiliary disorders 19 (6.3) 8 (2.7) 
Hepatitis Cd 58 (19.3) 57 (19.1) 
Hepatitis Be 5 (1.7) 9 (3.0) 
HIV positive 1 (0.3) 0 (0) 
Tinea pedisf 23 (7.7) 20 (6.7) 
Present or recent IV drug useg 89 (29.7) 80 (26.8) 
Previous ABSSSI lesion 91 (30.3) 74 (24.8) 
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Type of primary infection 300 (100) 298 (100) 
Primary diagnosis as ABSSSI 300 (100) 298 (100) 
Cellulitis or erysipelas 192 (64.0) 191 (64.1) 
Wound infections 68 (22.7) 68 (22.8) 
Major cutaneous abscess 40 (13.3) 39 (13.1) 
ABSSSI with secondary bacteremia 5 (1.7) 3 (1.0) 
At least one Gram-positive organism identified 
at baseline,h n/N (%) 
113 (37.7%) 126 (42.3%) 
Gram-positive aerobes 113/113 (100) 123/126 (97.6) 
Staphylococcus aureus 79/113 (69.9)i 95/126 (75.4)j 
MSSA 51/113 (45.1) 64/126 (50.8) 
MRSA 29/113 (25.7) 32/126 (25.4) 
Streptococcus anginosus 23/113 (20.4) 23/126 (18.3) 
Streptococcus pyogenes 4/113 (3.5) 6/126 (4.8) 
Streptococcus mitis group 4/113 (3.5) 4/126 (3.2) 
Polymicrobial Gram-positive infection 13 (11.5) 25 (19.8) 
Mixed Gram-positive and Gram-negative 
infection 
5 (4.4) 7 (5.6) 
Disease characteristics   
Fever,k n/N (%) 67/292 (22.9) 84/296 (28.4) 
WBC (>10,000 or <4000 cells/mm3), n/N (%) 153/298 (51.3) 149/297 (50.2) 
Immature neutrophils (>10%), n/N (%)  7/160 (4.4) 7/156 (4.5) 
Lymphadenopathy, n (%) 219/299 (73.2) 213/298 (71.5) 
Lesion size, cm2    
Median 302.5 306.75 
Mean (SD) 491.6 (618.1) 428.3 (391.7) 
Range 75.0–6272.0 77.0–2664.0 
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Anatomical location of ABSSSI,l n (%)   
Lower leg 120 (40.0) 115 (38.6) 
Foot dorsal 33 (11.0) 32 (10.7) 
Thigh 27 (9.0) 25 (8.4) 
Buttock 16 (5.3) 16 (5.4) 
Head 15 (5.0) 16 (5.4) 
Forearm 15 (5.0) 20 (6.7) 
Upper arm 16 (5.3) 22 (7.4) 
Otherm 60 (20.0) 64 (21.5) 
Duration of intravenous treatment, days   
Median 4.0 3.0 
Mean (SD) 4.2 (2.3) 4.0 (2.3) 
ABSSSI: acute bacterial skin and skin structure infection; BMI: body mass index; HIV: human 774 
immunodeficiency virus; ITT: intent to treat; MRSA: methicillin-resistant Staphylococcus aureus; 775 
MSSA: methicillin-susceptible S. aureus; IV: intravenous; SD: standard deviation; WBC, white blood 776 
cell count 777 
a N1=299 778 
b N1=295 779 
c N1=295 780 
d All but one non-Asian patients 781 
e Five Asian patients in each arm 782 
f All Asian patients 783 
g All but one non-Asian patients 784 
h Patients could have had mixed or polymicrobial infection 785 
i One patient in the tedizolid arm had been infected with both MSSA and MRSA; data are shown ‘by 786 
patient’ 787 
j One patient in the linezolid arm had been infected with both MSSA and MRSA; data are shown ‘by 788 
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patient’ 789 
k Body temperature 38°C (oral), 38.5°C (tympanic) or 39°C (rectal) 790 
l Patients could have had multiple anatomical sites provided they were contiguous 791 
m Includes (but not limited to): face, hand dorsal, shoulder, abdomen, axilla, back, limb, etc. 792 
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Table 2. Primary and secondary efficacy endpoints in different analysis populations 793 
 
Tedizolid 
phosphate 
200 mg QD,  
6 days 
Linezolid 
600 mg BD,  
10 days 
Treatment 
difference  
(95% CI) 
Programmatic early clinical 
response at 48–72 hours in ITT 
population, n/N (%) 
N=300 N=298   
Responder 226 (75.3) 238 (79.9) –4.6% (–11.2; 2.2) 
Non-responder or indeterminate 74 (24.7) 60 (20.1)   
Non-responder 51 (17.0) 41 (13.8)   
Indeterminate 23 (7.7) 19 (6.4)   
Programmatic early clinical 
response at 48–72 hours in mITT 
population, n/N (%) 
N1=292 N1=297   
Responder 226 (77.4) 238 (80.1) –2.7% (–9.4; 3.9) 
Non-responder or indeterminate 66 (22.6) 59 (19.9)   
Non-responder 51 (17.5) 41 (13.8)   
Indeterminate 15 (5.1) 18 (6.1)   
Programmatic clinical response at 
EOT in ITT population, n/N (%) 
N=300 N=298   
Clinical success 246 (82.0) 251 (84.2) –2.2% (–8.3; 3.8) 
Clinical failure or indeterminate 54 (18.0) 47 (15.8)   
Clinical failure 34 (11.3) 30 (10.1)   
Indeterminate 20 (6.7) 17 (5.7)   
Programmatic clinical response at 
EOT in CE-EOT population, n/N (%) 
N=242 N=243   
Clinical success 217 (89.7) 223 (91.8) –2.1% (–7.4; 3.2) 
Clinical failure 25 (10.3) 20 (8.2)   
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Investigator’s assessment of clinical 
response at PTE visit in ITT 
population, n/N (%) 
N=300 N=298   
Clinical success 239 (79.7) 244 (81.9) –2.2% (–8.6; 4.1) 
Clinical failure or indeterminate 61 (20.3) 54 (18.1)   
Clinical failure 25 (8.3) 21 (7.0)   
Indeterminate 36 (12.0) 33 (11.1)   
Investigator's assessment of clinical 
response at PTE in CE-PTE 
population, n/N (%) 
N1=219 N1=231   
Clinical success 198 (90.4) 216 (93.5) –3.1% (–8.4; 2.0) 
Clinical failure 21 (9.6) 15 (6.5)  
BD: twice daily; CE: clinically evaluable; CI: confidence interval; EOT: end of therapy; ITT: intent to 794 
treat; mITT: modified ITT (i.e. exclusion of patients who never received study drug); PTE: post-therapy 795 
evaluation; QD: once daily 796 
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Table 3. Investigator assessment of clinical success at the post-therapy evaluation 797 
visit by baseline pathogen in the microbiological intent-to-treat population 798 
Speciesa Tedizolid phosphate 
N=113 
Linezolid 
N=126 
Gram-positive aerobes, n/N1 (%)     
Staphylococcus aureusb 60/79 (75.9) 70/95 (73.7) 
MSSA 40/51 (78.4) 51/64 (79.7) 
MRSA 21/29 (72.4) 20/32 (62.5) 
Streptococcus anginosus 21/23 (91.3) 18/23 (78.3) 
Streptococcus pyogenes 2/4 (50.0) 5/6 (83.3) 
Streptococcus mitis group 4/4 (100) 4/4 (100) 
MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible S. aureus 799 
n: number of patients with clinical success; N1: number of patients with confirmed pathogen at 800 
baseline 801 
a Other Gram-positive pathogens in very small numbers included: Staphylococcus haemolyticus, 802 
Streptococcus canis, Staphylococcus lugdunensis, Streptococcus agalactiae, Enterococcus faecalis, 803 
Enterococcus spp., Gemella morbillorum, Mycobacterium fortuitum, Clostridium tertium, Finegoldia 804 
magna, Propionibacterium avidum; b One patient in the tedizolid arm and one patient in the linezolid 805 
arm had been infected with both MSSA and MRSA; data are shown ‘by patient’.806 
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Table 4. Overall safety: treatment-emergent adverse events (safety population) 807 
 
Tedizolid 
phosphate 
200 mg, QD, 
6 days 
N=292 
Linezolid  
600 mg, BD, 10 
days 
N=297 
Any TEAE, n (%) 145 (49.7) 136 (45.8) 
Mild 95 (32.5) 89 (30.0) 
Moderate 37 (12.7) 40 (13.5) 
Severe 12 (4.1) 7 (2.4) 
Missing 1 (0.3) 0 (0) 
Drug-related TEAE, n (%) 61 (20.9) 47 (15.8) 
Serious TEAE, n (%) 11 (3.8) 8 (2.7) 
Drug-related serious TEAE, n (%) 0 (0) 0 (0) 
TEAE leading to discontinuation of study drug, n 
(%) 
6 (2.1) 6 (2.0) 
Serious TEAE leading to discontinuation of study 
drug, n (%) 
0 (0) 3 (1.0) 
Any TEAE leading to death, n (%) 0 (0) 0 (0) 
BD: twice daily; QD: once daily; TEAE: treatment-emergent adverse event 808 
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Table 5. Drug-related treatment-emergent adverse events occurring in ≥1% of 809 
patients in either treatment arm (safety population) 810 
System Organ Class  
    Preferred Terma 
Tedizolid phosphate 
200 mg, QD, 6 days 
N=292 
Linezolid 
600 mg, BD, 10 days 
N=297 
Gastrointestinal disorders, n (%)     
Nausea 11 (3.8) 11 (3.7) 
Diarrhea 4 (1.4) 3 (1.0) 
Vomiting 4 (1.4) 2 (0.7) 
General disorders and administration 
site conditions, n (%) 
    
Fatigue 1 (0.3) 3 (1.0) 
Nervous system disorders, n (%)     
Headache 2 (0.7) 4 (1.3) 
Hepatobiliary disorders, n (%)     
Hepatic function abnormal 2 (0.7) 4 (1.3) 
Vascular disorders, n (%)     
Phlebitis reported 8 (2.7) 0 
BD: twice daily; QD: once daily 811 
a Any one patient is counted only once within each Preferred Term of any primary System Organ 812 
Class 813 
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Figure 1. Patient flow through the study 814 
 815 
 816 
* Reason for no treatment: withdrew consent: n=7; non-compliance with study drug: n=1 817 
** Reason for no treatment: lost to follow up: n=1 818 
† Patients could have been excluded for more than one reason 819 
‡ Included all patients who were eligible for inclusion in CE-PTE analysis set with at least one Gram-820 
positive pathogen at baseline 821 
^ Blood culture was negative at screening but positive at a later time point, and the collection of a 822 
blood sample was clinically indicated for culture   823 
824 
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Figure 2. Per-patient overall favorable microbiological response* at post-therapy 825 
evaluation visit 826 
 827 
 828 
CI: confidence interval; ME: microbiological evaluable; MITT: microbiological intent to treat 829 
* Favorable response was equivalent to 'Presumed eradication' for the different baseline infection 830 
types 831 
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Figure 1. Patient flow through the study.
* Reason for no treatment: withdrew consent: n=7; non-compliance with study drug: n=1; ** Reason for no treatment: lost to follow up: n=1;
† Patients could have been excluded for more than one reason; ‡ Included all patients who were eligible for inclusion in CE-PTE analysis 
set with at least one Gram-positive pathogen at baseline; ^ Blood culture was negative at screening but positive at a later time point, and 
the collection of a blood sample was clinically indicated for culture.
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CI: confidence interval; ME: microbiological evaluable; MITT: microbiological intent-to-treat; PTE: post-
treatment evaluation visit. * Favorable response was equivalent to 'Presumed eradication' for the different 
baseline infection types. 
87/113 95/126 79/84 86/95 
Figure 2. Per-patient overall favorable microbiological response* at post-therapy evaluation visit. 
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